Pål Stenmark, PhD

CEO, founder


Pål has more than 20 years experience in academia working on structure-based drug design and research on the botulinum neurotoxins.


Pål is Professor of Neurochemistry at Stockholm University (Sweden).

Geoffrey Masuyer, PhD



A structural biologist, Geoffrey has worked on the development of toxin-based therapeutics for more than 15 years, including academic collaborations with Ipsen BioInnovation (UK), and Applied Molecular Transport Inc. (USA) at the University of Bath (UK) and Stockholm University (Sweden).